期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
卵巢浆液性肿瘤富含AT的结合域1A基因、BAF250a蛋白及血清糖类抗原125表达差异性研究 被引量:1
1
作者 闫丽隽 孙立新 宋莉莉 《肿瘤研究与临床》 CAS 2020年第5期318-322,共5页
目的探讨不同卵巢浆液性肿瘤组织中富含AT的结合域1A(ARID1A)基因及其编码蛋白BAF250a以及血清糖类抗原125(CA125)表达的差异性。方法收集2015年8月至2018年9月就诊于山西省肿瘤医院并行手术治疗的术后病理结果证实为卵巢浆液性肿瘤的9... 目的探讨不同卵巢浆液性肿瘤组织中富含AT的结合域1A(ARID1A)基因及其编码蛋白BAF250a以及血清糖类抗原125(CA125)表达的差异性。方法收集2015年8月至2018年9月就诊于山西省肿瘤医院并行手术治疗的术后病理结果证实为卵巢浆液性肿瘤的97例患者肿瘤组织。其中,良性病变(浆液性囊腺瘤、浆液性纤维腺瘤、浆液性表面乳头状瘤)11例(对照组),交界性病变(AP)(非典型增生性浆液性肿瘤)21例,低级别浆液性癌(LC)35例,高级别浆液性癌(HC)30例(Ⅰ~Ⅳ期分别有5、7、9、9例)。采用实时荧光定量聚合酶链反应检测各组肿瘤组织中ARID1A mRNA表达量,采用蛋白质印迹法及免疫组织化学染色法分别检测肿瘤组织中BAF250a蛋白表达量和形态,采用酶联免疫吸附法检测各组患者血清CA125浓度。比较各组ARID1A基因、BAF250a蛋白及血清CA125表达差异,并分析HC组患者三者表达与临床分期的相关性。结果对照组、AP组、LC组、HC组患者肿瘤组织中ARID1A mRNA相对表达量、BAF250a蛋白相对表达量依次降低,血清CA125浓度依次增高,差异均有统计学意义[1.37±0.02、0.68±0.03、0.42±0.04、0.29±0.14,F=3.753,P=0.008;1.33±0.11、0.81±0.11、0.51±0.11、0.39±0.11,F=10.753,P=0.001;(23.72±2.26)、(36.83±13.11)、(412.55±41.71)、(529.96±61.44)U/ml,F=10.440,P=0.003]。免疫组织化学法检测显示,对照组、AP组、LC组、HC组BAF250a蛋白高表达率分别为90.0%(10/11)、85.7%(18/21)、70.0%(21/35)、33.3%(10/30)。在HC组中,血清CA125浓度随临床分期增高而增加[Ⅰ~Ⅳ期分别为(461.33±23.18)、(483.51±41.21)、(507.78±33.41)、(543.19±47.82)U/ml,r=0.510,P=0.015],ARID1A mRNA、BAF250a蛋白相对表达量随临床分期增加而降低(Ⅰ~Ⅳ期分别为0.33±0.10、0.28±0.11、0.21±0.08、0.17±0.07,r=-0.329,P=0.030;3.83±0.13、3.08±0.16、2.61±0.18、2.07±0.13,r=-0.651,P=0.002)。结论卵巢浆液性肿瘤组织中ARID1A基因及其编码蛋白BAF250a表达降低、CA125表达增高或可提示肿瘤恶变及侵袭度增高。 展开更多
关键词 卵巢肿瘤 基因 ARID1A 蛋白 baf250a 糖类抗原125
原文传递
Binding of Human SWI1 ARID Domain to DNA without Sequence Specificity: A Molecular Dynamics Study
2
作者 孙茜 朱涛 +1 位作者 王常玉 马丁 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2015年第4期469-476,共8页
SWI 1 is a member of a new class of tumor DNA-binding proteins named as the AT-rich in- teraction domain family (ARID), and considered to bind with AT base pairs specifically. Genomic and functional data support ARI... SWI 1 is a member of a new class of tumor DNA-binding proteins named as the AT-rich in- teraction domain family (ARID), and considered to bind with AT base pairs specifically. Genomic and functional data support ARID1A as a tumor suppressor because AR1D1A/BAF250a (SWI1) subunit of the SWI/SNF chromatin-remodeling complex has emerged as recurrently mutated in a broad array of tumor types. But the crystal structure of SWI1 has not been solved as yet. Using docking and molecular dynamics, we predicted the DNA interaction pattern of human SWI1 ARID and made comparisons with the other two representative ARID family members, human Mrf-2 ARID and Drosophila Dri ARID. Dynamic results revealed that the N-terminal and loop L1 of SWI1 ARID bound with the DNA major groove, while the loop L2 and helix H6 bound with the minor groove. Moreover, it was found that SWI1 ARID bound with DNA apparently in a sequence-nonspecific manner. It was concluded that SWI1 ARID can form stable complex with sequence-nonspecific DNA segment comparing to Mrf-2 ARID/DNA and Dri ARID/DNA sequence-specific complexes. 展开更多
关键词 AT-rich interaction domain family 1A (ARID) baf250a Mrf-2 ARID Dri ARID pro- tein-DNA interaction ovarian cancer
暂未订购
上一页 1 下一页 到第
使用帮助 返回顶部